Staphylococcus schleiferi is a Gram-positive coccus bacterium first discovered in 1988 that is typically associated with skin and ear infections in dogs, cats and birds. It is infrequently described as a human pathogen. There are, however, emerging reports of S. schleiferi infections in diverse clinical scenarios in humans, particularly in patients with weakened immune systems. S. schleiferi may be underrecognised due to limitations in routine microbiology diagnostic protocols and mislabelling as other Staphylococcus sp. We present a rare case of S. schleiferi diabetic foot osteomyelitis with subsequent bacteraemia in an immunocompromised host.
Introduction: Emergency department (ED) visits related to flare-ups of inflammatory bowel disease (IBD) are becoming more prevalent. There are many potentially dangerous complications and sequelae of uncontrolled IBD.
Case Report: We report a case of a middle-aged woman who presented with a few hours of severe abdominal pain, nausea, and vomiting. Given her hemodynamic instability, she was sent urgently for computed tomography, which showed an incomplete small bowel malrotation, mesenteric volvulus, and high-grade small bowel obstruction with evolving ischemia. The patient underwent exploratory laparotomy to resect most of her small intestines. Biopsies later revealed active Crohn’s disease.
Conclusion: Patients with flare-ups of IBD are common in the ED, but very few present with a midgut volvulus later in life. Our case is unique and adds to the literature due to the dramatic consequences of undiagnosed Crohn’s disease in a patient with intermittent symptoms and extensive workup spanning over two decades.
At week 24, ALT normalization was reached by 53% of arm B and 38% of arm C (vs 6% of arm A, p, 0.0001). One patient treated with 2 mg BLV achieved an HBsAg reduction $1 log 10 IU/mL at week 24. Conclusion: This Phase 3 trial confirms that monotherapy with BLV is safe and well tolerated in patients with compensated cHDV infection. 24 weeks of treatment with BLV was associated with significant HDV RNA declines and improvements in biochemical disease activity. These findings further support the conditional approval of BLV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.